DSF, primarily an inhibitor of the enzyme aldehyde dehydrogenase (ALDH), achieves its anti-tumor effect by targeting several other intracellular pathways, including Nuclear Factor kappa-light-chain-enhancer of activated B-cells (NF-κB), and nuclear protein localization protein-4 (NPL-4), a mediator of the p97 ATPase cascade with higher expression in medulloblastoma cells and in other cancers of CNS origin [19, 20]. Here, LDHA is linked to cancer.